Lung inflammation in cystic fibrosis: Pathogenesis and novel therapies

Clinical Biochemistry

Volumn 47, Issue 7-8, 2014, Pages 539-546

  Dhooghe, Barbara ^a   Noël, Sabrina ^a   Huaux, François ^a   Leal, Teresinha ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

CFTR; Cystic fibrosis; Cytokines; Inflammation; New therapies

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMITRIPTYLINE; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; CORTICOSTEROID; IBUPROFEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KB 001A; KB001A; MIGLUSTAT; N 6022; N6022; OMEGA 3 FATTY ACID; SILDENAFIL; UNCLASSIFIED DRUG; CYTOKINE;

ANTIBIOTIC THERAPY; CELL DIFFERENTIATION; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LEUKOCYTE MIGRATION; LOW DRUG DOSE; MACROPHAGE; MOUSE MODEL; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PORCINE MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FUNCTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; ANIMAL; IMMUNOLOGY; METABOLISM; PNEUMONIA;

ANIMALS; CYSTIC FIBROSIS; CYTOKINES; HUMANS; PNEUMONIA;

EID: 84900315796     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.12.020     Document Type: Review

References (110)

1. Boucher R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007, 261:5-16.
2. Tarran R., Button B., Picher M., Paradiso A.M., Ribeiro C.M., Lazarowski E.R., et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem 2005, 280:35751-35759.
3. Stutts M.J., Rossier B.C., Boucher R.C. Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J Biol Chem 1997, 272:14307-14340.
4. Ismailov I.I., Awayda M.S., Jovov B., Berdiev B.K., Fuller C.M., Dedman J.R., et al. Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. J Biol Chem 1996, 271:4725-4732.
5. Smith D.J., Gaffney E.A., Blake J.T. Modelling mucociliary clearance. Respir Physiol Neurobiol 2008, 163:178-188.
6. Button B., Boucher R.C. Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respir Physiol Neurobiol 2008, 163:189-201.
7. Rubin B.K. Mucus structure and properties in cystic fibrosis. Paediatr Respir Rev 2007, 8:4-7.
8. Dosanjh A., Muchmore E.A. Expression of DeltaF508 Cystic Fibrosis Transmembrane Regulator (CFTR) decreases membrane sialylation. Open Respir Med J 2009, 3:79-84.
9. Imundo L., Barasch J., Prince A., Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A 1995, 92:3019-3023.
10. Schroeder T.H., Zaidi T., Pier G.B. Lack of adherence of clinical isolates of Pseudomonas aeruginosa to asialo-GM(1) on epithelial cells. Infect Immun 2001, 69:719-729.
11. Pier G.B., Grout M., Zaidi T.S. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 1997, 94:12088-12093.
12. Lawrence R., Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 1993, 342:465-469.
13. Kurlandsky L.E., Bennink M.R., Webb P.M., Ulrich P.J., Baer L.J. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol 1994, 18:211-217.
14. Prescott W.A., Johnson C.E. Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 2005, 25:555-573.
15. Coste T.C., Deumer G., Reychler G., Lebecque P., Wallemacq P., Leal T. Influence of pancreatic status and sex on polyunsaturated fatty acid profiles in cystic fibrosis. Clin Chem 2008, 54:388-395.
16. Steinkamp G., Demmelmair H., Ruhl-Bagheri I., von der Hardt H., Koletzko B. Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2000, 31:418-423.
17. Lloyd-Still J.D., Johnson S.B., Holman R.T. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am J Clin Nutr 1981, 34:1-7.
18. Roulet M., Frascarolo P., Rappaz I., Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997, 156:952-956.
19. Coste T.C., Armand M., Lebacq J., Lebecque P., Wallemacq P., Leal T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem 2007, 40:511-520.
20. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004, 350:560-569.
21. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr (-/-) mice. Proc Natl Acad Sci U S A 1999, 96:13995-40000.
22. Mimoun M., Coste T.C., Lebacq J., Lebecque P., Wallemacq P., Leal T., et al. Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. J Nutr 2009, 139:2358-2364.
23. Teichgräber V., Ulrich M., Endlich N., Riethmüller J., Wilker B., De Oliveira-Munding C.C., et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:382-391.
24. Wojewodka G., De Sanctis J.B., Radzioch D. Ceramide in cystic fibrosis: a potential new target for therapeutic intervention. J Lipids 2011, 2011:674968.
25. Becker K.A., Henry B., Ziobro R., Riethmüller J., Gulbins E. Lipids in cystic fibrosis. Expert Rev Respir Med 2011, 5:527-535.
26. Ziobro R., Henry B., Edwards M.J., Lentsch A.B., Gulbins E. Ceramide mediates lung fibrosis in cystic fibrosis. Biochem Biophys Res Commun 2013, 434:705-709.
27. Fayon M., Airway-Inflammation Group, Société Française de Mucoviscidose CF-emerging therapies: modulation inflammation. Paediatr Respir Rev 2006, 7:S170-S174.
28. Belessis Y., Dixon B., Hawkins G., Pereira J., Peat J., Macdonald R., et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. Am J Respir Crit Care Med 2012, 185:862-873.
29. Armstrong D.S., Hook S.M., Jamsen K.M., Nixon G.M., Carzino R., Carlin J.B., et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005, 40:500-510.
30. Rosenfeld M., Gibson R.L., Mcnamara S., Emerson J., Burns J.L., Castile R., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001, 32:356-366.
31. Pillarisetti N., Williamson E., Linnane B., Skoric B., Robertson C.F., Robinson P., et al. Infection, inflammation and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011, 184:75-81.
32. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
33. Puchelle E., Bajolet O., Abély M. Airway mucus in cystic fibrosis. Paediatr Respir Rev 2002, 3:115-119.
34. Collins J., Devos G., Hudes G., Rosenstreich D. Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma Allergy 2012, 5:65-70.
35. Tan H.L., Regamey N., Brown S., Bush A., Lloyd C.M., Davies J.C. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011, 184:252-258.
36. Sorio C., Buffelli M., Angiari C., Ettorre M., Johansson J., Vezzalini M., et al. Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. PLoS One 2011, 6:e22212.
37. Hartl D., Latzin P., Hordijk P., Marcos V., Rudolph C., Woischnik M., et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007, 13:1423-1430.
38. Hayes E., Pohl K., Mcelvaney N.G., Reeves E.P. The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch Immunol Ther Exp (Warsz) 2011, 59:97-112.
39. Sagel S.D., Wagner B.D., Anthony M.M., Emmett P., Zemanick E.T. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012, 186:857-865.
40. Cohen-Cymberknoh M., Kerem E., Ferkol T., Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax 2013, 68:1157-1162.
41. Brennan S., Cooper D., Sly P.D. Directed neutrophil migration to IL-8 is increased in cystic fibrosis: a study of the effect of erythromycin. Thorax 2001, 56:62-64.
42. Bonfield T.L., Konstan M.W., Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999, 104:72-78.
43. Karp C.L., Flick L.M., Park K.W., Softic S., Greer T.M., Keledjian R., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004, 5:388-392.
44. Alexis N.E., Muhlebach M.S., Peden D.B., Noah T.L. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros 2006, 5:17-25.
45. Galli F., Battistoni A., Gambari R., Pompella A., Bragonzi A., Pilolli F., et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta 2012, 1822:690-713.
46. Rønne Hansen C., Pressler T., Høiby N., Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 2006, 5:245-251.
47. Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002, 15:194-222.
48. Bragonzi A., Farulla I., Paroni M., Twomey K.B., Pirone L., Lorè N.I., et al. Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response. PLoS One 2012, 7:e52330.
49. Moss R.B. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010, 16:598-603.
50. Hartl D. Immunological mechanisms behind the cystic fibrosis-ABPA link. Med Mycol 2009, 47(Suppl. 1):S183-S191.
51. Latzin P., Hartl D., Regamey N., Frey U., Schoeni M.H., Casaulta C. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2008, 31:36-42.
52. Lebecque P., Leonard A., De Boeck K., De Baets F., Malfroot A., Casimir G., et al. Early referral to cystic fibrosis specialist centre impacts on respiratory outcome. J Cyst Fibros 2009, 8:26-30.
53. Cystic Fibrosis Foundation Patient Registry. 2012 Annual Data Report 2013, Cystic Fibrosis Foundation, Bethesda, Maryland.
54. Cigana C., Assael B.M., Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2007, 51:975-981.
55. Cigana C., Nicolis E., Pasetto M., Assael B.M., Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2006, 350:977-982.
56. Wiszniewski L., Jornot L., Dudez T., Pagano A., Rochat T., Lacroix J.S., et al. Long-term cultures of polarized airway epithelial cells from patients with cystic fibrosis. Am J Respir Cell Mol Biol 2006, 34:39-48.
57. Kerem B., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
58. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzerlczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
59. Wilke M., Buijs-Offerman R.M., Aarbiou J., Colledge W.H., Sheppard D.N., Touqui L., et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros 2011, 10(Suppl. 2):S152-S171.
60. Scholte B.J., Davidson D.J., Wilke M., De Jonge H.R. Animal models of cystic fibrosis. J Cyst Fibros 2004, 3(Suppl. 2):183-190.
61. van Doorninck J.H., French P.J., Verbeek E., Peters R.H., Morreau H., Bijman J., et al. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 1995, 14:4403-4411.
62. Belgisch Mucoviscidose Register -Registre Belge de la Mucoviscidose-2007. Annual Data Report, Belgium 2007.
63. Colledge W.H., Abelia B.S., Southern K.W., Ratcliff R., Jiang C., Cheng S.H., et al. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat Genet 1995, 10:445-452.
64. Zeiher B.G., Eichwald E., Zabner J., Smith J.J., Puga A.P., Mccray P.B., et al. A mouse model for the delta F508 allele of cystic fibrosis. J Clin Invest 1995, 96:2051-2064.
65. Legssyer R., Huaux F., Lebacq J., Delos M., Marbaix E., Lebecque P., et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 2006, 7:134.
66. Meyer M., Huaux F., Gavilanes X., van den Brûle S., Lebecque P., Lison D., et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009, 41:590-602.
67. Elizur A., Cannon C.L., Ferkol T.W. Airway inflammation in cystic fibrosis. Chest 2008, 133:489-495.
68. Gavilanes X., Huaux F., Meyer M., Lebecque P., Marbaix E., Lison D., et al. Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice. J Cyst Fibros 2009, 8:203-210.
69. Huaux F., Noel S., Dhooghe B., Panin N., Lo Re S., Lison D., et al. Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis. PLoS One 2013, 8:e64341.
70. Lubamba B., Huaux F., Lebacq J., Marbaix E., Dhooghe B., Panin N., et al. Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice. J Cyst Fibros 2012, 11:266-273.
71. Mall M., Grubb B.R., Harkema J.R., O'neal W.K., Boucher R.C. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004, 10:487-493.
72. Zhou Z., Treis D., Schubert S.C., Harm M., Schatterny J., Hirtz S., et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med 2008, 178:1245-1256.
73. Hofmann T., Stutts M.J., Ziersch A., Rückes C., Weber W.M., Knowles M.R., et al. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am J Respir Crit Care Med 1998, 157:1844-1849.
74. Hirsh A.J., Sabater J.R., Zamurs A., Smith R.T., Paradiso A.M., Hopkins S., et al. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2004, 311:929-938.
75. Li Z., Engelhardt J.F. Progress toward generating a ferret model of cystic fibrosis by somatic cell nuclear transfer. Reprod Biol Endocrinol 2003, 1:83.
76. Welsh M.J., Rogers C.S., Stoltz D.A., Meyerholz D.K., Prather R.S. Development of a porcine model of cystic fibrosis. Trans Am Clin Climatol Assoc 2009, 120:149-162.
77. Fisher J.T., Zhang Y., Engelhardt J.F. Comparative biology of cystic fibrosis animal models. Methods Mol Biol 2011, 742:311-334.
78. Rogers C.S., Stoltz D.A., Meyerholz D.K., Ostedgaard L.S., Rokhlina T., Taft P.J., et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008, 321:1837-1841.
79. Pezzulo A.A., Tang X.X., Hoegger M.J., Alaiwa M.H., Ramachandran S., Moninger T.O., et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012, 487:109-113.
80. Chang E.H., Pezzulo A.A., Meyerholz D.K., Potash A.E., Wallen T.J., Reznikov L.R., et al. Sinus hypoplasia precedes sinus infection in a porcine model of cystic fibrosis. Laryngoscope 2012, 122:1898-1905.
81. Chen J.H., Stoltz D.A., Karp P.H., Ernst S.E., Pezzulo A.A., Moninger T.O., et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 2010, 143:911-923.
82. http://www.cff.org/research/DrugDevelopmentPipeline/.
83. Elkins M.R., Robinson M., Rose B.R., Harbour C., Moriarty C.P., Marks G.B., et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-240.
84. Jaques A., Daviskas E., Turton J.A., Mckay K., Cooper P., Stirling R.G., et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008, 133:1388-1396.
85. Griese M., App E.M., Duroux A., Burkert A., Schams A. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum. Pulm Pharmacol Ther 1997, 10:21-27.
86. Mccoy K., Hamilton S., Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996, 110:889-895.
87. Cheng K., Ashby D., Smyth R.L. Oral steroids for long-term use in cystic fibrosis. Cochrane Database Syst Rev 2013, 6:CD000407.
88. Balfour-Lynn I.M., Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2012, 11:CD001915.
89. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
90. Jaffé A., Francis J., Rosenthal M., Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998, 351:420.
91. Wolter J., Seeney S., Bell S., Bowler S., Masel P., Mccormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
92. Equi A., Balfour-Lynn I.M., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
93. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., Jais J.P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006, 61:895-902.
94. Mayer-Hamblett N., Saiman L., Lands L.C., Anstead M., Rosenfeld M., Kloster M., et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemp Clin Trials 2013, 36:99-105.
95. Saiman L., Mayer-Hamblett N., Anstead M., Lands L.C., Kloster M., Goss C.H., et al. Open-label, follow- study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 2012, 47:641-648.
96. Ratjen F., Saiman L., Mayer-Hamblett N., Lands L.C., Kloster M., Thompson V., et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa. Chest 2012, 142:1259-1266.
97. Lubamba B., Lecourt H., Lebacq J., Lebecque P., De Jonge H., Wallemacq P., et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008, 177:506-515.
98. Lubamba B., Lebacq J., Reychler G., Marbaix E., Wallemacq P., Lebecque P., et al. Inhaled PDE5 inhibitors restore chloride transport in cystic fibrosis mice. Eur Respir J 2011, 37:72-78.
99. Taylor-Cousar J.L., Curran-Everett D., Felton L., Nichols D., Saavedra M.T., Nick J.A. Oral sildenafil administration decreases sputum elastase in adults with cystic fibrosis. Pediatr Pulmonol Suppl 2013, 36:289.
100. De Vizia B., Raia V., Spano C., Pavlidis C., Coruzzo A., Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J Parenter Enteral Nutr 2003, 27:52-57.
101. Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Boulat O., et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr 2006, 25:418-427.
102. Norez C., Noel S., Wilke M., Bijvelds M., Jorna H., Melin P., et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006, 508:2081-2086.
103. Noël S., Wilke M., Bot A.G., De Jonge H.R., Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008, 325:1016-1023.
104. Lubamba B., Lebacq J., Lebecque P., Vanbever R., Leonard A., Wallemacq P., et al. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009, 179:1022-1028.
105. Dechecchi M.C., Nicolis E., Mazzi P., Cioffi F., Bezzerri V., Lampronti I., et al. Modulators of sphingolipid metabolism reduce lung inflammation. Am J Respir Cell Mol Biol 2011 Oct, 45(4):825-833.
106. Zaman K., Carraro S., Doherty J., Henderson E.M., Lendermon E., Liu L., et al. S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol Pharmacol 2006, 70:1435-1442.
107. Blonder J.P., Quinney N.L., Looker D., Sun X., Gentzsch M., Scoggin C., et al. Intestinal current measurement to assess modulation of F508del-CFTR function by GSNOR inhibitor treatment in vivo. Pediatr Pulmonol Suppl 2013, 36:209.
108. Blonder J.P., Look K., Sun X., Sui J., Qiu J., Scoggin C., et al. A novel GSNOR inhibitor with potent bronchodilatory effects and CFTR potentiation activity. Pediatr Pulmonol Suppl 2013, 36:208.
109. Sun X., Sui J., Qiu J., Stout A.M., Verderber E.L., Blonder J.P., et al. Next generation F508del-CFTR correctors using a YFP based high throughput screening assay. Pediatr Pulmonol Suppl 2013, 36:216.
110. Wanner A., Arce A.D., Pardee E. Novel therapeutic uses of alpha-1 antitrypsin: a window to the future. COPD 2012, 9:583-588.